Olympus Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Bob White
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Olympus (TSE:7733) Might Have The Makings Of A Multi-Bagger
Sep 30
Earnings Miss: Olympus Corporation Missed EPS By 50% And Analysts Are Revising Their Forecasts
Aug 12A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)
Jul 25Subdued Growth No Barrier To Olympus Corporation's (TSE:7733) Price
Jul 09Olympus (TSE:7733) Seems To Use Debt Quite Sensibly
Jun 17Olympus Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 16Does This Valuation Of Olympus Corporation (TSE:7733) Imply Investors Are Overpaying?
Apr 22The Returns At Olympus (TSE:7733) Aren't Growing
Apr 07Investors Appear Satisfied With Olympus Corporation's (TSE:7733) Prospects
Mar 22These 4 Measures Indicate That Olympus (TSE:7733) Is Using Debt Reasonably Well
Feb 01A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)
Jan 17
Cloud-Powered Endoscopy Innovation Fuels Revenue Growth In The Medical Devices Industry
Approval of AI endoscopy devices in the U.S. and Europe is expected to drive revenue growth through improved clinical outcomes and procedural efficiency.Olympus' (TSE:7733) Strong Earnings Are Of Good Quality
Nov 15Olympus Corporation's (TSE:7733) Share Price Could Signal Some Risk
Nov 07CEO
Bob White (63 yo)
Mr. Robert John White, also known as Bob, serves as Representative Executive Officer, President & CEO of Olympus Corporation since June 1, 2025 and its Director since June 26, 2025. He is Member of the Sup...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Representative Executive Officer | 13.6yrs | JP¥379.00m | 0.025% ¥ 531.8m | |
| Executive Officer & Global General Counsel | 1.8yrs | JP¥175.00m | no data | |
| Executive Officer and Chief Manufacturing & Supply Officer | no data | JP¥125.00m | no data | |
| Executive Officer of Gastrointestinal Solutions | 5.8yrs | JP¥522.00m | no data | |
| Executive Officer & Chief Strategy Officer | no data | JP¥300.00m | no data | |
| Executive Officer & Chief Quality Officer | 3.8yrs | JP¥274.00m | no data | |
| Executive Officer & Chief Medical Officer | 1.8yrs | JP¥156.00m | no data | |
| Representative Executive Officer | less than a year | no data | no data | |
| Executive Officer & CFO | 1.6yrs | no data | no data | |
| Vice President of Accounting | no data | no data | no data | |
| Executive Officer & CTO | less than a year | no data | no data | |
| Corporate Officer & Chief Information Officer | 3.8yrs | JP¥734.00m | no data |
Experienced Management: 7733's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Representative Executive Officer | 13.6yrs | JP¥379.00m | 0.025% ¥ 531.8m | |
| Representative Executive Officer | less than a year | no data | no data | |
| Independent Outside Director | 6.4yrs | no data | 0.00065% ¥ 13.7m | |
| Independent Outside Director | 3.4yrs | no data | 0.00053% ¥ 11.2m | |
| Independent Outside Director | 1.4yrs | no data | 0.00028% ¥ 5.9m | |
| Independent Outside Director | 6.4yrs | no data | no data | |
| Independent Outside Director | 2.4yrs | no data | 0.00044% ¥ 9.3m | |
| Director | 2.4yrs | no data | 0.0022% ¥ 47.3m | |
| Independent Outside Director | 4.4yrs | no data | 0.00092% ¥ 19.4m | |
| Independent Outside Director | 3.4yrs | no data | 0.0010% ¥ 22.1m | |
| Independent Outside Director | less than a year | no data | no data |
Experienced Board: 7733's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 20:35 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Olympus Corporation is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Warren Lau | Aletheia Analyst Network Limited |
| Masahiro Nakanomyo | Barclays |
| Ritsuo Watanabe | BofA Global Research |